护理学报 ›› 2023, Vol. 30 ›› Issue (19): 41-44.doi: 10.16460/j.issn1008-9969.2023.19.041
胃癌患者报告结局评估工具的研究进展
张馥丽a, 王丹妮a, 叶红a, 蔡姣芝b
- 广东省中医院 a.肿瘤科; b.护理部,广东 广州 510120
摘要： 目的 对目前国内外胃癌患者报告结局评估工具进行综述,以期为胃癌患者报告结局评估工具的构建和应用提供依据。方法 检索国内外相关文献,对胃癌患者报告结局工具进行文献检索、整理和分析。结果 汇总了5种特异性量表和部分普适性评估工具,对各种测评工具的主要内容、应用领域、特点、优势以及局限性进行分析和总结。结论 未来的研究可对已研制成功的本土化量表进行再考评、多中心验证、推广应用;同时探索如何将患者报告结局融入临床实践,推进患者报告结局在临床实践中的常规应用。
中图分类号:
- R473.57
| [1] Baratell C, Turco CGC, Lacidogna G, et al.The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients'quality of life[J]. Supportive Care in Cancer,2019,27(12):4697-4704.DOI:10.1007/s00520-019-04777-2. [2] 国家药监局药审中心.关于发布《患者报告结局在药物临床研发中应用的指导原则(试行)》的通告(2021年第62号)[EB/OL].[2023-07-22].https://www.cde.org.cn/main/news/viewInfoCommon/c2f79c22e8678241b030c71523eb300c. [3] Di maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized Trials[J].J Clin Oncol,2015,33(8):910-915.DOI:10.1200/JCO.2014.57.9334. [4] 张鲁敏,顾芬,任皎皎,等.护理领域患者报告结局的研究热点分析[J].医院管理论坛, 2021,38(5): 50-55.DOI:10.3969/j.issn.1671-9069.2021.05.014. [5] 杨智慧, 缪景霞, 廖荣荣,等.肿瘤免疫治疗护理相关研究的关键词可视化分析[J]. 护理学报, 2023,30(1):12-16.DOI:10.16460/j.issn1008-9969.2023.01.012. [6] Woo A, Fu T, Popovic M, et al.Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer[J]. Ann Palliat Med, 2016,5(1): 13-21.DOI: 10.3978/j.issn.2224-5820.2016.01.02. [7] Blazeby JM, Conroy T, Bottomley A, et al.Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer[J]. Eur JCancer, 2004,40(15):2260-2268.DOI:10.1016/j.ejca.2004.05.023. [8] 刘伟琳, 杨舸, 芮煜华, 等. EORTC QLQ-STO22量表对我国胃癌患者有效性的验证[J]. 肿瘤研究与临床, 2016,28(9):595-599.DOI:10.3760/cma.j.issn.1006-9801.2016.09.005. [9] Hu Y, Vos EL, Baser RE, et al.Longitudinal analysis of Quality-of-Life recovery after gastrectomy for cancer[J]. Ann Surg Oncol,2021,28(1):48-56.DOI:10.1245/s10434-020-09274-z. [10] Garland SN, Pelletier G, Lawe A, et al.Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument[J]. Cancer, 2011,117(6):1302-1312.DOI:10.1002/cncr.25556. [11] Debb SM, Arnold B, Perez B,et al.Validation of the FACT-Gastric cancer quality of life questionnaire for use in Spanish-speaking countries[J]. Psycho-Oncology, 2011,20(1): 19-27.DOI:10.1002/pon.1698. [12] Maeda H, Sato M, Kobayashi M, et al.Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants[J]. Supportive Care in Cancer, 2016,24(11): 4515-4521.DOI:10.1007/s00520-016-3290-3. [13] Schutter K, Schulz C, Middelberg-Bisping K. Impact of gastric cancer treatment on quality of life of patients[J]. Best Pract Res Clin Gastroenterol,2021,50-51:101727.DOI:10.1016/j.bpg.2021.101727. [14] Zhu Y, Wu X, Wang W, et al.Acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy[J]. J Pain Symptom Manage, 2022,63(2):210-220.DOI:10.1016/j.jpainsymman.2021.09.009. [15] Zhou HJ, So JB, Yong WP, et al.Validation of the functional assessment of cancer therapy-gastric module for the Chinese population[J]. Health Qual Life Outcomes, 2012,10: 145.DOI:10.1186/1477-7525-10-145. [16] 孟祥敏,王倩,闫荣,等.结直肠癌患者报告结局评估工具及临床应用的研究进展[J].中华护理杂志, 2022, 57(9): 1094-1099.DOI:10.3761/j.issn.0254-1769.2022.09.010. [17] Wang XS, Williams LA, Eng C, et al.Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI)[J]. Cancer, 2010,116(8): 2053-2063.DOI:10.1002/cncr.24920. [18] Wang XS, Wang Y, Guo H, et al.Chinese version of the M. D. Anderson Symptom Inventory:validation and application of symptom measurement in cancer patients[J]. Cancer, 2004,101(8): 1890-1901.DOI:10.1002/cncr.20448. [19] Chen R, Yang S, Xu Z, et al.Validation and Application of the Chinese Version of the M.D. Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI-C)[J]. J Pain Symptom Manage,2019,57(4):820-827.DOI:10.1016/j.jpainsymman.2019.01.007. [20] 胡月,段培蓓,侯庆梅,等.胃癌术后首次化疗患者症状群与生活质量的研究[J].解放军护理杂志, 2018,35(17): 12-16.DOI: 10.3969/j.issn.1008-9993.2018.17.003. [21] Maharaj AD, Samoborec S, Evans SM, et al.Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review[J]. HPB, 2020,22(2): 187-203.DOI:10.1016/j.hpb.2019.09.002. [22] Li N, Lu J, Xia D, et al.Serum biomarkers predict adjuvant chemotherapy-associated symptom clusters in radical resected colorectal cancer patients[J]. J Gastrointest Oncol, 2022,13(1): 197-209.DOI:10.21037/jgo-21-904. [23] Nakada K, Ikeda M, Takahashi M, et al.Characteristics and clinical relevance of postgastrectomy syndrome assessment scale (PGSAS)-45: newly developed integrated questionnaires for assessment of living status and quality of life in postgastrectomy patients[J].Gastric Cancer,2015,18(1): 147-158.DOI:10.1007/s10120-014-0344-4. [24] Misawa K, Terashlma M, Uenosono Y, et al.Evaluation of postgastrectomy symptoms after distal gastrectomy with Billroth-I reconstruction using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45)[J]. Gastric Cancer, 2015,18(3): 675-681.DOI:10.1007/s10120-014-0407-6. [25] Kinami S, Nakamura N, Zhiyong J, et al.Severity of postgastrectomy syndrome and quality of life after advanced gastric cancer radical gastrectomy[J].Mol Clin Oncol, 2020,13(2): 133-140.DOI:10.3892/mco.2020.2061. [26] 袁燕,张楠,王家林.胃癌患者生命质量测定量表及测量结果应用研究进展[J].中华肿瘤防治杂志, 2021, 28(9): 708-712.DOI:10.16073/j.cnki.cjcpt.2021.09.13. [27] Hu X, Zhao F, Yu H, et al.GC-PROM: validation of a patient-reported outcomes measure for Chinese patients with gastric cancer[J]. BMC Cancer, 2020,20(1): 41.DOI:10.1186/s12885-020-6518-z. [28] Dueck AC, Mendoza TR, Mitchell SA, et al.Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)[J].JAMA Oncol, 2015,1(8):1051-1059.DOI:10.1001/jamaoncol.2015.2639. [29] Yoon J, Sim SH, Kang D, et al.Reliability and validity of the Korean language version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events[J]. J Pain Symptom Manage,2020,59(5):1082-1088.DOI:10.1016/j.jpainsymman.2020.01.015. [30] Kawguchi T, Azuma K, Sano M, et al.The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events[J]. J Patient Rep Outcomes, 2017,2(1):2.DOI:10.1186/s41687-017-0022-5. [31] Hagelstein V, Ortland I, Wilmer A, et al.Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. Ann Oncol, 2016,27(12): 2294-2299.DOI:10.1093/annonc/mdw422. [32] Yang S, Chen L, Liu Y, et al.Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events[J]. BMC Cancer,2021,21(1):860.DOI:10.1186/s12885-021-08610-0. [33] Watanabe SM, Nekolaichuk C, Beaumont C, et al.A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients[J]. J Pain Symptom Manage, 2011,41(2):456-468.DOI:10.1186/s12885-021-08610-0. [34] Hui D, Bruera E.The Edmonton Symptom Assessment System 25 years later: past, present, and future developments[J]. J Pain Symptom Manage,2017,53(3):630-643.DOI:10.1016/j.jpainsymman.2016.10.370. [35] Dong Y, Chen H, Zheng Y, et al.Psychometric validation of the Edmonton Symptom Assessment System in Chinese Patients[J]. J Pain Symptom Manage, 2015,50(5):712-717.DOI:10.1016/j.jpainsymman.2015.05.018. [36] Merchant SJ, Kong W, Brundage M, et al.Symptom evolution in patients with esophageal and gastric cancer receiving palliative chemotherapy: a population-based study[J].Ann Surg Oncol,2021, 28(1):79-87.DOI:10.1245/s10434-020-09289-6. [37] Bubis LD, Dellbasiv V, Davis LE, et al.Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life[J]. Support Care Cancer, 2021,29(1): 515-524.DOI:10.1007/s00520-020-05501-1. [38] 刘佳文,赵芬,张艳娜,等.胃癌患者报告结局量表的研制与计量心理学特征考核[J].中国卫生统计,2019,36(3):330-333. [39] 曹娟,李方,田雅丽,等.早期肺癌术后患者报告结局量表编制及信效度检验[J].护理学杂志, 2023,38(7):35-39.DOI:10.3870/j.issn.1001-4152.2023.07.03. |
| [1] | 李姗姗, 黄红艳, 李媛媛, 黎江静. 终末期慢性肾脏病患者治疗决策需求的研究进展[J]. 护理学报, 2023, 30(7): 38-43. |
| [2] | 陶娟, 潘红英, 陈慧颖, 蓝莹, 鲜雪梅. 医务人员手卫生评估工具的研究进展[J]. 护理学报, 2023, 30(6): 26-30. |
| [3] | 万丽丽, 宋春美, 郑翠霞. 消化性溃疡患者自我报告结局评估工具的研究进展[J]. 护理学报, 2023, 30(19): 37-40. |
| [4] | 叶念思, 胡慧, 邓蓓. 重复性负性思维的研究进展[J]. 护理学报, 2023, 30(14): 32-36. |
| [5] | 张颖, 刘雪琴, 刘晓辉, 聂亚杰, 章晓菲, 赵洁, 代楠, 王肖阳. 血液透析疲乏患者报告结局评估工具临床应用的研究进展[J]. 护理学报, 2023, 30(13): 38-41. |
| [6] | 雷丹, 卞薇. 角膜疾病患者报告结局评估工具的研究进展[J]. 护理学报, 2023, 30(12): 40-44. |
| [7] | 陈鑫容, 常承婷, 杨婕, 李卡. 胃癌患者围术期症状群的研究进展[J]. 护理学报, 2023, 30(1): 33-36. |
| [8] | 刘贺, 郑蔚, 苏闪闪, 王丹丹, 刘梦丽, 瞿小凤. 205例胃癌复发患者自我怜悯现状及影响因素分析[J]. 护理学报, 2022, 29(9): 1-4. |
| [9] | 陈勇, 彭思意, 刘小保, 李坤艳, 魏涛, 李旭英. 肿瘤专科医院I期临床研究病房的建设与实践[J]. 护理学报, 2022, 29(5): 32-36. |
| [10] | 胡蓉, 宁宁, 陈佳丽, 唐秀美, 李佩芳, 王雅磊, 胡秀英. 皮肤撕裂伤知识评估工具的汉化及信效度检验[J]. 护理学报, 2022, 29(18): 18-22. |
| [11] | 夏超, 段培蓓, 杨玲, 杨丽萍, 韩斯璇, 王阿芹. 166例胃癌术后化疗患者症状群内前哨症状的调查[J]. 护理学报, 2021, 28(8): 44-49. |
| [12] | 黄翱黎, 王妤. 护士主导的尿管拔除评估工具研究进展[J]. 护理学报, 2021, 28(23): 32-35. |
| [13] | 杨利灵, 陆群峰, 江艳, 唐平, 季涧琳. 1型糖尿病患儿自我管理评估工具的研究进展[J]. 护理学报, 2021, 28(22): 36-39. |
| [14] | 邓博, 刘宁, 杨琳. 临床实践项目持续性评估工具的范围综述[J]. 护理学报, 2021, 28(13): 40-45. |
| [15] | 支梦佳, 王懿范, 胡琳琳. 基于连续性记录与评估工具对养老机构老年人生命质量及影响因素的分析[J]. 护理学报, 2020, 27(19): 1-5. |
|